Lower-, Higher-Dose Elagolix Beneficial for Endometriosis

This article originally appeared here.
Share this content:
Lower-, Higher-Dose Elagolix Beneficial for Endometriosis
Lower-, Higher-Dose Elagolix Beneficial for Endometriosis

MONDAY, May 22, 2017 (HealthDay News) -- Lower- and higher-dose elagolix are beneficial for women with endometriosis, according to research published online May 19 in the New England Journal of Medicine to coincide with the 13th World Congress on Endometriosis, held from May 17 to 20 in Vancouver, Canada.

Hugh S. Taylor, M.D., from the Yale School of Medicine in New Haven, Conn., and colleagues conducted two phase 3 trials (Elaris Endometriosis I and II [EM-I and EM-II]) to examine the impact of lower-dose (150 mg once daily) and higher-dose (200 mg twice daily) elagolix versus placebo for women with surgically diagnosed endometriosis and moderate or severe endometriosis-associated pain. A total of 872 and 817 women, respectively, underwent randomization in Elaris EM-I and Elaris EM-II; 74.9 and 77.4 percent, respectively, completed the intervention.

The researchers found that the percentage of women who had a clinical response with respect to dysmenorrhea was 46.4 and 75.8 percent in the lower- and higher-dose elagolix groups, respectively, compared with 19.6 percent in the placebo group in Elaris EM-I; the corresponding percentages were 43.4 and 72.4 versus 22.7 percent in Elaris EM-II. With respect to non-menstrual pelvic pain, the corresponding percentages were 50.4 and 54.5 versus 36.5 percent in Elaris EM-I, and 49.8 and 57.8 versus 36.5 percent in Elaris EM-II.

"Both higher and lower doses of elagolix were effective in improving dysmenorrhea and non-menstrual pelvic pain during a six-month period in women with endometriosis-associated pain," the authors write.

The study was funded by AbbVie, the manufacturer of elagolix.

Abstract
Full Text
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

For Hepatitis B Patients, Aspirin Tied to Lower Risk of HCC

For Hepatitis B Patients, Aspirin Tied to Lower ...

5 years of aspirin therapy linked to significantly lower incidence of hepatocellular carcinoma

High Percentage of HIV-Diagnosed Women Not in Care

High Percentage of HIV-Diagnosed Women Not in Care

62 percent of women with positive test had previously received the diagnosis but no care

CDC Updates Zika Guidance for Infant Care

CDC Updates Zika Guidance for Infant Care

Recommendations include evaluation and management of infants with possible infection

is free, fast, and customized just for you!

Already a member?

Sign In Now »